Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 7 consecutive quarters of double digit growth.
Click here to learn more ›
Development of a Patient-Centric Exit Study to Contextualize and Assess Meaningfulness of a Potential Treatment for Hypoactive Sexual Desire Disorder (HSDD)
